Controversies in the management of ESBLproducing Enterabacterales. Clinical Implications
Rev. esp. quimioter
; 35(Supl. 3): 41-45, Oct. 2022.
Article
em En
| IBECS
| ID: ibc-210747
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Extended-spectrum β-lactamases (ESBL)-producing organisms currently represent a major health problem. Although recently published guidelines still consider carbapenems as the treatment of choice for ESBL-producing infections, it is necessary to find non-carbapenem β-lactams as alternatives to reduce the effects associated with their overutilization. In this review we focus on these alternatives to carbepenem use. It is possible that piperacillin-tazobactam may be an alternative in clinical settings with low inoculum infections like urinary tract infections. Newer β-lactam-β-lactamase inhibitors (BLBLIs) are potential options too. The current available data support the efficacy of both ceftazidime-avibactam and ceftolozane-tazobactam against susceptible ESBL-producing Enterobacterales (ESBL-E). We are waiting for the results of MERINO-3 study to confirm whether ceftolozane-tazobactam is a good option versus meropenem for treating bloodstream infections caused by ESBL- or AmpC-producing Enterobacterales. (AU)
Palavras-chave
Texto completo:
1
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Inibidores de beta-Lactamases
Limite:
Humans
Idioma:
En
Revista:
Rev. esp. quimioter
Ano de publicação:
2022
Tipo de documento:
Article